Table 6.
Hemoglobin F and pulmonary complications in hemoglobin SS subjects in the Walk-PHaSST cohort
| General clinical manifestations | |||||
|---|---|---|---|---|---|
| N | >3 pain episodes |
Leg ulcers | Hb g/dL | LDH U/L* | |
| Hb F 0–9% | 103 | 21.4% | 23.3% | 8.1 (0.1) | 513 (493–534) |
| Hb F 10–19% | 40 | 7.5% | 25.0% | 8.7 (0.2) | 428 (395–455) |
| Hb F 20%+ | 9 | 11.1% | 0% | 10.0 (0.4) | 380 (337–433) |
| P | 0.07 | 0.3 | <0.001 | 0.011 | |
| Pulmonary complications | |||||
| N | O2 sat <95% |
Acute chest syndrome |
TRV ≥3.0 m/sec |
BNP >160 ng/L |
|
| Hb F 0–9% | 103 | 34.3% | 55.3% | 10.2% | 16.7% |
| Hb F 10–19% | 40 | 15.0% | 60.0% | 13.1% | 23.7% |
| Hb F 20+ | 9 | 0% | 33.3% | 11.1% | 0% |
| P | 0.003 | 0.6 | 0.7 | 0.8 | |
| Left Ventricular Size and Function | |||||
| N |
LV Diastolic Area (cm2) |
LV Mass Index (g/m2) |
Ejection Fraction |
LV lateral E/Ea |
|
| Hb F 0–9% | 396 | 34 (29–39) | 109 (89–130) | 61 (58–66) | 6.4 (5.2–8.0) |
| Hb F 10–19% | 98 | 34 (30–40) | 105 (89–123) | 62 (58–66) | 6.5 (5.4–8.6) |
| Hb F 20+ | 46 | 33 (28–37) | 90 (81–112) | 63 (60–68) | 5.9 (4.7–7.0) |
| P | 0.3 | 0.024 | 0.2 | 0.12 | |
*
Adjusted for site